Harfst & Associates’s Eli Lilly LLY Stock Holding History

Harfst & Associates’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Buy	1,844 +315	+21%	+$322K	0.34%	53
2026 Q1	$1.41M	Buy	+1,529	New	+$1.55M	0.25%	66
2017 Q3	–	Sell	-160	Closed	-$13K	–	156
2017 Q2	$13K	Sell	160 -2,567	-94%	-$209K	0.01%	185
2017 Q1	$229K	Buy	+2,727	New	+$218K	0.1%	63
2016 Q3	–	Sell	-29,228	Closed	-$2.3M	–	88
2016 Q2	$2.3M	Buy	+29,228	New	+$2.2M	0.93%	19
2016 Q1	–	Sell	-29,653	Closed	-$2.5M	–	163
2015 Q4	$2.5M	Sell	29,653 -2,115	-7%	-$176K	1.02%	13
2015 Q3	$2.66M	Buy	31,768 +27,756	+692%	+$2.34M	1.17%	10
2015 Q2	$335K	Buy	+4,012	New	+$306K	0.19%	35

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Harfst & Associates's LLY Position: Q2 2026 in Review

Harfst & Associates increased its Eli Lilly (LLY) stake by 21% in Q2 2026, buying an estimated $322K and bringing the position to 1,844 shares worth $2.21M. The position accounts for 0.34% of the portfolio, ranked #53.

Harfst & Associates first reported a position in LLY in Q2 2015 and has held it in 8 quarters since. The position peaked at $2.66M in Q3 2015. 2,641 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Harfst & Associates held 1,844 shares of Eli Lilly worth $2.21M as of Q2 2026.
Harfst & Associates bought 315 Eli Lilly shares in Q2 2026, an estimated $322K.
Eli Lilly made up 0.34% of Harfst & Associates's portfolio in Q2 2026, its #53 holding.
Harfst & Associates first reported a position in Eli Lilly in Q2 2015 and has held it in 8 quarters since.
Harfst & Associates's Eli Lilly position peaked at $2.66M in Q3 2015.
2,641 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Harfst & Associates's 13F filing for Q2 2026, filed 31 Jul 2026.